We build and empower transformational healthcare
companies by pushing innovation boundaries
and forming operating platforms

Awards & Recognition

PEI 300

June 2020

CBC Group ranked as the top dedicated Asia private equity firm for the second consecutive year and is also the youngest firm among its healthcare-focused peers

01.jpg

5 Chinese GPs to watch

August 2018

Which first-time firms are likely to be the next big thing? Private Equity International examines china’s rising stars

02.jpg

2019 Exit of the Year – IPO

November 2019

CBC Group successfully exited its investment in Innovent Biologics,a Chinese cancer drug developer, realizing as 3.4x multiple on invested capital for its partners in April 2019 following a Hong Kong IPO in October 2018. The company has 17 drugs in its pipeline, of which the four most advanced are biosimilars. It had raised more than $560 million across several private funding rounds

2019 Deal of the Year – Small Cap

November 2019

CBC Group committed $49 million in funding to AffaMed Therapeutics in January 2019. It established AffaMed to work with Samsung Bioepis on the development and commercialization of four biosimilar drug candidates in China. The investment was driven by a recognition that there is huge demand for affordable biologic drugs in China, yet most local players don’t qualify as biosimilar producers and most global players aren’t targeting China

info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.